-

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences.

  • Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis, MN on Wednesday, May 28.
  • Jefferies Global Healthcare Conference 2025 in New York, NY. Presentation on Thursday, June 5 at 10:30 a.m. ET.
  • Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL. Fireside chat on Monday, June 9 at 3:20 p.m. ET.

To listen to the webcast for the June 5th and June 9th events, please visit the Events & Presentations section of CareDx’s Investor Relations website at: www.investors.com.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Contacts

Investor Relations
Caroline Corner
investor@caredx.com

Industry:

CareDx, Inc.

NASDAQ:CDNA
Release Versions
English

Contacts

Investor Relations
Caroline Corner
investor@caredx.com

More News From CareDx, Inc.

CareDx Reports First Quarter 2025 Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Reported first quarter revenue of $84.7 million, increased 18% year-over-year Testing services revenue of $61.9 million, increased 15% year-over-year, and testing services volume of approximately 47,100, increased 12% year-over-year GAAP net loss of $10.4 million, non-GAAP net income of $5.4 million, and positive adjusted...

CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx, together with study collaborators, presented new scientific evidence on the use of AlloSure® Lung in clinical practice at the International Society for Heart and Lung Transplanta...

CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx, together with study collaborators from leading transplant centers, will present the latest advancements in clinical evidence supporting its transplant care solutions at the Inter...
Back to Newsroom